Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterCorrespondence

Dr. Wolfe replies

FREDERICK WOLFE
The Journal of Rheumatology February 2016, 43 (2) 453; DOI: https://doi.org/10.3899/jrheum.151128
FREDERICK WOLFE
National Data Bank for Rheumatic Diseases, and University of Kansas School of Medicine, Wichita, Kansas, USA.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fwolfe{at}arthritis-research.org
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

This is the fifth letter to me from Dr. Toda in the form of a letter to the editor since the publication of the 2010 criteria. Here is another answer. By either the American College of Rheumatology 2010 or the modified criteria of 2011, the only way to satisfy fibromyalgia (FM) criteria is by meeting 1 of the following conditions: widespread pain (WPI) ≥ 7 and symptom severity scale (SSS) ≥ 5 or WPI 3–6 and SSS ≥ 91,2. If one adds together the WPI and SSS, the result is the polysymptomatic distress (PSD) score or, as the scale has also been called, the FM symptom (FS) scale or score. Dr. Toda is correct that the PSD is “useful to evaluate FM severity.” Because the probability of meeting the FM criteria increases with increasing PSD score, the PSD can serve as an approximate measure of FM diagnosis. In my review of the literature, the FS scale misclassifies 4% to 8% of cases when compared [(WPI ≥ 7 and SSS ≥ 5) or (WPI 3–6 and SSS ≥ 9)], so that it is probably not a good idea to use cutpoints for diagnosis in the individual patient.

I believe that Dr. Toda is confused when he speaks of a “change of cutpoint from 13 to 12.” We did not change cutpoints. The PSD cutpoint is the cutpoint that leads to the least misclassification of cases and non-cases when many patients are studied, and it can vary from study to study. So, in some studies that might be 12 and in others 13, and still others yet a different number. The cutpoint is not a number that I or some criteria determine. It is determined by the distribution of scores and cases in the study sample. For example, suppose there are 200 cases: 100 non-cases with PSD scores between 0 and 11, and 100 cases with PSD scores between 12 and 31. In that case, the cutpoint will be 12 and there will be no misclassification. However, in another sample there are 100 non-cases with PSD scores between 0 and 11, and 50 non-cases with PSD scores between 12 and 15, and 50 cases with PSD scores between 16 and 31. It is clear that a cutpoint of 12 would misclassify 50 cases, but a cutpoint of 16 would misclassify no cases.

As to what is the clinical value of a difference in the PSD score of 1 unit, I refer Dr. Toda to an article in The Journal that gives insight into differences in PSD scores (and also Figure 1 of that article, a good example of standard criteria vs PSD cutpoint as criteria)3. Ultimately, the importance of differences is a decision for clinicians.

There is not enough space to reply to your question about the meaning of FM. But we have done this elsewhere and we recommend that article to you4.

REFERENCES

  1. 1.↵
    1. Wolfe F,
    2. Clauw DJ,
    3. Fitzcharles MA,
    4. Goldenberg DL,
    5. Katz RS,
    6. Mease P,
    7. et al.
    The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600–10.
    OpenUrlCrossRef
  2. 2.↵
    1. Wolfe F,
    2. Clauw D,
    3. Fitzcharles MA,
    4. Goldenberg D,
    5. Häuser W,
    6. Katz RS,
    7. et al.
    Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011;38:1113–22.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Wolfe F,
    2. Walitt BT,
    3. Rasker JJ,
    4. Katz RS,
    5. Häuser W
    . The use of polysymptomatic distress categories in the evaluation of fibromyalgia (FM) and FM severity. J Rheumatol 2015;42:1494–501.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Wolfe F
    . Editorial: the status of fibromyalgia criteria. Arthritis Rheumatol 2015;67:330–3.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 43, Issue 2
1 Feb 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dr. Wolfe replies
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dr. Wolfe replies
FREDERICK WOLFE
The Journal of Rheumatology Feb 2016, 43 (2) 453; DOI: 10.3899/jrheum.151128

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dr. Wolfe replies
FREDERICK WOLFE
The Journal of Rheumatology Feb 2016, 43 (2) 453; DOI: 10.3899/jrheum.151128
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Proton Pump Inhibitor Use and Its Significant Association With an Increased Incidence of Intestinal Behçet Disease
  • Dr. Murakami et al reply
  • Dr. Rusinovich-Lovgach et al reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire